Navigation Links
Reportlinker Adds Anti-aging Products and Services: The Global Market Report
Date:9/3/2009

TES TREATMENT MARKET 145

TABLE 144 (CONTINUED) 146

FIGURE 18 TREATMENT WITH INSULIN OR ORAL MEDICATION AMONG BABY BOOMERS IN UNITED STATES, 2007 (%) 147

FIGURE 19 ESTIMATED NUMBER OF NEW CASES OF DIAGNOSED DIABETES IN PEOPLE BY AGE GROUP IN UNITED STATES, 2007 147

FIGURE 19 (CONTINUED) 148

CNS 148

TABLE 145 GLOBAL CNS MARKET BY REGION, THROUGH 2013 ($ MILLIONS) 148

Alzheimer's Disease 148

Less Awareness and Poor Attention of FDA towards CNS Disorders 149

Top CNS Disease Drugs 150

TABLE 146 TOP ALZHEIMER'S DISEASE DRUGS, 2007 150

TABLE 147 TOP ANTI-DEPRESSION DRUGS, 2007 150

TABLE 148 FDA-APPROVED PARKINSON'S DISEASE DRUGS 150

TABLE 148 (CONTINUED) 151

TABLE 149 NEW PRODUCTS--ALZHEIMER 151

TABLE 150 CLINICAL PHASE PRODUCTS 151

TABLE 150 (CONTINUED) 152

TABLE 151 RESEARCH PHASE 152

TABLE 151 (CONTINUED) 153

CARDIAC HEALTH 153

TABLE 152 GLOBAL CVD MARKET, THROUGH 2013 ($ MILLIONS) 153

Anti-aging CVD Drugs 154

TABLE 153 NEW PRODUCTS- CVD 154

TABLE 153 (CONTINUED) 155

SEXUAL DYSFUNCTION 155

TABLE 154 GLOBAL SEXUAL DYSFUNCTION MARKET BY REGION, THROUGH 2013 ($ MILLIONS) 156

TABLE 155 TOP THREE ED DRUGS, 2007 ($ BILLIONS) 156

TABLE 156 NEW PRODUTS--SEXUAL DYSFUNCTION 156

TABLE 156 (CONTINUED) 157

GLOBAL ANTI-AGING BOOMER MARKET FOR EYE CARE 157

TABLE 157 GLOBAL EYE CARE MARKET, THROUGH 2013 ($ MILLIONS) 157

TABLE 158 FDA-APPROVED GLAUCOMA DRUGS 158

TABLE 159 TOP GLAUCOMA DRUGS, 2007 ($ MILLIONS) 158

TABLE 160 NEW PRODUCTS--GLAUCOMA DRUGS 159

TABLE 161 TOP THREE FDA-APPROVED AMD DRUGS, 2007 159

TABLE 162 CLINICAL PHASE AMD PRODUCTS 160

FITNESS 160

TABLE 163 FITNESS IMPACT ON DISEASES/DISORDERS 160

TABLE 164 FITNESS APPLICATION MARKET, THROUGH 2013 ($ MILLIONS) 161

TAB
'/>"/>

SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report
2. Reportlinker Adds Healthcare Information Technology Report
3. Reportlinker Adds World Markets for Fermentation Ingredients Report
4. Reportlinker Adds The Market for Minimally Invasive Medical Devices Report
5. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
6. Reportlinker Adds 2008/2009 Healthcare Research Review Report
7. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
8. Reportlinker Adds Pediatric Health Care Products and Services Report
9. Reportlinker Adds the Dental Market: Techniques, Equipment and Materials Report
10. Reportlinker Adds Membrane & Separation Technology News Review, 2008 Report
11. Reportlinker Adds Commercial Amino Acids Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Sermo ( http://www.sermo.com ), the world,s ... results of a new Sermo Vitals Report titled ... The report examines physician dialog about diabetes over ... of a variety of topics, including the therapies ... and candid/verbatim comments on issues related to diabetes. ...
(Date:12/16/2009)... WILMINGTON, Delaware, December 16 While ... outsource their accurate forecast models,for new and ... provides,integrated patient-based forecast solutions to various players. ... I, phase II, as well as phase,III. ... launch, product life cycle,management, market entry strategy, ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... visitors can earn a free 21-count one week trial bottle sample ... ... MI (PRWEB) December 16, 2009 -- ImmuneResponse247.com announces ... Sample” of Immune Response 247™ 6 Mushroom Formula , with ... Immune Response 247™ 6 Mushroom Formula is packaged in FDA approved ...
(Date:12/16/2009)... The cost of hearing aids has been brought into reach for ... new subscription based hearing plan. , ... (PRWEB) December ... into reach for many Houstonians with the announcement by Hearing Haven, ... benefit by hearing better on the job, and want to improve ...
Breaking Medicine News(10 mins):Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 2Health News:Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes 3Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Monthly Subscription Hearing Aid Plan Announced for Houston 2
... Lee Baca has justified placing Paris Hilton under house arrest ... seems that Judge Michael T Sauer who ordered her ... was conning doctors. ,On Larry Kings show, Larry Waldie, ... that Sauer didn't care, and that he even hinted that ...
... Many a families summer vacations mean piling into the car ... marred by frequent nausea and vomiting . This means some ... ,Carsickness, a variant of motion sickness, happens when the ... fast and in what direction the body is moving, says ...
... a clinical stage biopharmaceutical company developing targeted monoclonal ... C virus infection, today announced initiation of ... safety and efficacy of its tumor necrosis therapy ... (GBM), a deadly form of brain cancer. ...
... I trials studying REP8839, a novel topical antibiotic that ... skin pathogens including methicillin-resistant S. aureus (MRSA). ... topically applied REP8839 appears safe, well-tolerated and associated with ... which is desirable for a topical antibiotic treatment. Based ...
... Accera, Inc. announced today that recent data from its Phase ... AD may effectively be thought of and treated as diabetes ... to be caused by the accumulation of amyloid beta plaques ... shown that inducing insulin resistance in the brains of mice ...
... drug, Gatifloxacin, is a better treatment for drug- resistant ... a team of researchers led by Dr Buddha Basnyat ... ,As part of the study, researchers compared the effect ... recommended by the World Health Organisation for treating enteric ...
Other Medicine News:Health News:Car Sickness for the Little Ones can Be Prevented 2Health News:Car Sickness for the Little Ones can Be Prevented 3Health News:Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial 2Health News:Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
(Date:12/16/2009)... VIEW, Calif., Dec. 16 ChemoCentryx, Inc. ... in a Phase 2 clinical trial of CCX354, ... specifically target the CCR1 chemokine receptor for the ... is a highly potent and selective antagonist of ... of immune cells, such as monocytes and macrophages, ...
(Date:12/16/2009)... , ... Recruits a Total of Over,640 patients Ahead ... ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical ... innovative treatments for eye,disease, vascular disease and ... enrolment of the second Phase III trial ...
(Date:12/15/2009)... Volcano Corporation (Nasdaq: VOLC ), ... tools - including Fractional Flow Reserve (FFR), Intravascular ... Tomography (OCT) - designed to enhance the diagnosis ... announced today the placement of over 2,500 s5 ... consoles was first launched in April 2006, with ...
Breaking Medicine Technology:ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 2ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 3ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 4ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis 5ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 1Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 2Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 3Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 4Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 5Cantel Medical Reports 85 25 Increase in Net Income EPS of 240 37 vs 240 20 for Quarter Ended October 31 2009 on 10 25 Sales Increase 6859 6BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 1BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 2BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 3BioCryst Pharmaceuticals Elects Charles A Sanders to its Board of Directors 6856 4Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 1Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research 6853 2
... participates in a national study to explore new ... Jan. 12 Reproductive Partners Medical Group ... for their excellent IVF success rates and national ... a national, multi-center study exploring new progesterone delivery ...
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral and other infectious diseases, today ... IDX184, a liver-targeted nucleotide prodrug candidate for the treatment ... with the U.S. Food and Drug Administration (FDA). The ...
Other Medicine Technology:Reproductive Partners Participates in New IVF Progesterone Delivery System Study 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4
... aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand ... Volume Range (ul) ... 1.0~2.0 Imprecision(%) ... 1 ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: